Biocon Limited

BSE:532523 Stock Report

Market Cap: ₹446.7b

Biocon Past Earnings Performance

Past criteria checks 4/6

Biocon has been growing earnings at an average annual rate of 9.7%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 21% per year. Biocon's return on equity is 7%, and it has net margins of 9.7%.

Key information

9.7%

Earnings growth rate

9.4%

EPS growth rate

Biotechs Industry Growth5.1%
Revenue growth rate21.0%
Return on equity7.0%
Net Margin9.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Biocon makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:532523 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24148,94114,39231,958-1,515
30 Jun 24147,66015,80830,286-1,110
31 Mar 24147,55710,22528,525-838
31 Dec 23146,12512,00226,439-119
30 Sep 23135,9994,98424,819-1,238
30 Jun 23124,5734,19723,998-2,156
31 Mar 23111,7424,62723,331-3,922
31 Dec 2298,0913,88122,558-5,606
30 Sep 2290,4226,17021,920-5,825
30 Jun 2285,6297,08421,305-5,768
31 Mar 2281,8406,48420,539-4,764
31 Dec 2175,8006,72720,252-4,050
30 Sep 2172,6326,54219,935-3,581
30 Jun 2171,7266,85219,466-3,530
31 Mar 2171,4317,40517,485-3,507
31 Dec 2068,9135,99616,778-3,607
30 Sep 2067,5716,36215,906-3,596
30 Jun 2065,7966,87015,120-3,568
31 Mar 2063,0057,77116,545-3,458
31 Dec 1963,1508,38513,910-3,001
30 Sep 1961,0778,52913,093-2,746
30 Jun 1958,5659,91912,449-2,757
31 Mar 1955,1449,05311,653-2,699
31 Dec 1851,5518,22011,087-2,421
30 Sep 1846,7226,96710,496-2,449
30 Jun 1843,1984,1089,862-1,993
31 Mar 1841,2343,7249,311-1,747
31 Dec 1738,7923,6958,708-1,522
30 Sep 1738,5894,4898,297-1,257
30 Jun 1738,3615,2687,846-1,324
31 Mar 1738,9116,1217,510-1,283
31 Dec 1640,48711,6337,458-1,472
30 Sep 1638,11010,9617,038-1,468
30 Jun 1636,5399,3886,665-1,378
31 Mar 1633,4745,5046,128-1,320
31 Dec 1532,9977,3678,595-202
30 Sep 1532,3257,2478,366-196
30 Jun 1531,5285,2078,223-272
31 Mar 1530,8984,9745,371-1,321
31 Dec 1429,8074,0917,565-386
30 Sep 1429,1684,2317,360-561
30 Jun 1429,0144,2327,137-585
31 Mar 1428,7734,1387,035-642

Quality Earnings: 532523 has a large one-off gain of ₹13.3B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 532523's current net profit margins (9.7%) are higher than last year (3.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 532523's earnings have grown by 9.7% per year over the past 5 years.

Accelerating Growth: 532523's earnings growth over the past year (188.8%) exceeds its 5-year average (9.7% per year).

Earnings vs Industry: 532523 earnings growth over the past year (188.8%) exceeded the Biotechs industry 148.9%.

Return on Equity

High ROE: 532523's Return on Equity (7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 02:52
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biocon Limited is covered by 43 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Harith AhamedAvendus Spark
Kunal RanderiaAxis Capital Limited